Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02510430 · ClinicalTrials.gov registry record · NA
The Plan and Stand Study: Reducing Sitting Time in Breast Cancer Survivors
A NA study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
NCT02510430: Completed NA study, sponsored by University of Wisconsin, Madison.
NCT02510430 is a NA study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 59 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02510430, a NA study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
Study Summary
Excessive sitting time (sedentary time) has been associated with risk of insulin resistance and other factors which may be relevant to breast cancer prognosis. This 8-week study tests different strategies for helping breast cancer survivors to modify their levels of sitting time. Participants will be assigned with equal likelihood to one of three groups (1) overall reduction in sitting time, (2) interruption of sitting time with standing breaks, and (3) usual care.
Primary Outcome
Feasibility of recruiting participants to the study
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL Re-Patterning Sitting Time Group
- BEHAVIORAL Reducing Sitting Time Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2015-11-30 |
| Est. Completion | 2018-01-24 |
| Phase | NA |
What the finished NCT02510430 record still lists
NCT02510430 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Usual Care is the first listed.
NCT02510430 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02510430 about?
NCT02510430 is a clinical study titled "The Plan and Stand Study: Reducing Sitting Time in Breast Cancer Survivors". Excessive sitting time (sedentary time) has been associated with risk of insulin resistance and other factors which may be relevant to breast cancer prognosis. This 8-week study tests different strategies for helping breast cancer survivors to modify their levels of sitting time. Participants will b...
What is the current status of trial NCT02510430?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2015-11-30. Estimated completion is 2018-01-24.
What interventions are being tested in trial NCT02510430?
The interventions under investigation include: Usual Care (BEHAVIORAL), Re-Patterning Sitting Time Group (BEHAVIORAL), Reducing Sitting Time Group (BEHAVIORAL).
Who is sponsoring clinical trial NCT02510430?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02510430's enrollment target sits among peer trials
59 1256th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI